Bibliography
- Daly JM, Fry WA, Little AG, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 2000;190(5):562-72
- Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265(10):1287-9
- Portale G, Hagen JA, Peters JH, et al. Modern 5-year survival of respectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg 2006;202:588-96
- Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349(23):2241-52
- Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-37
- Fiorica F, DiBona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925-30
- Plukker JT, van Westreenen HL. Staging in oesophageal cancer. Best Pract Res Clin Gastroenterol 2006;20(5):877-891
- de Graaf GW, Ayantunde AA, Parsons SL, et al. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol 2007;33(8):988-92
- van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 2008;98(3):547-57
- May A, Günter E, Roth F, et al. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial. Gut 2004;53(5):634-40
- Maish MS, DeMeester SR. Endoscopic mucosal resection as a staging technique to determine the depth of invasion of esophageal adenocarcinoma. Ann Thorac Surg 2004;78(5):1777-82
- Meyers BF, Downey RJ, Decker PA, et al. American College of Surgeons Oncology Group Z0060. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 2007;133(3):738-45
- Hagen JA, De Meester SR, Peters JH, et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en-bloc esophagectomies. Ann Surg 2001;234:520-30
- Altorki N, Kent M, Ferrara RN, et al. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002;236: 177-83
- Orringer MB, Marshall B, Chang AC, et al. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg 2007;246:363-72
- Kent MS, Schuchert M, Fernando H, et al. Minimally invasive esopahgectomy: state of the art. Dis Esophagus 2006;137-45
- Law S, Wong J. Lymph node dissection in surgical treatment of esophageal neoplasms. Surg Oncol Clin N Am 2007;16(1):115-31
- Dexter SP, Sue-Ling H, McMahon MJ, et al. Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer. Gut 2001;48(5):667-70
- Mulligan ED, Dunne B, Griffin M, et al. Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit. Eur J Surg Oncol 2004;30(3):313-7
- Siewert JR, Stein HJ, Feith M, et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001;234(3):360-7
- Dresner SM, Lamb PJ, Bennett MK, et al. The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction. Surgery 2001;129(1):103-9
- Feith M, Stein HJ, Siewert JR. Pattern of lymphatic spread of Barrett's cancer. World J Surg 2003;27(9):1052-7
- Swanson SJ, Batirel HF, Bueno R, et al. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg 2001;72(6):1918-24
- Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347(21):1662-9
- Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007;246(6):992-1000
- Chu KM, Law SY, Fok M, Wong J. A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg 1997;174(3):320-4
- Goldminc M, Maddern G, Le Prise E, et al. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg 1993;80(3):367-70
- Lerut T, Nafreux P, Moon J, et al. Three field lymphadenectomy in cancer of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease free survival, and outcome; a plea for adaptation of TNM classification in upper third esophageal carcinoma. Ann Surg 2004;240:962-72
- Lerut T, Moons J, Coosemans W, et al. Multidisciplinary treatment for advanced cancer of the esophagus and gastroesophageal junction: a European Centre approach. Surg Clin North America 2008;17:485-502
- Altorki N, Skinner D. Should en bloc esophagectomy be the standard of care for esophageal carcinoma? Ann Surg 2001;234(5):581-7
- Sihvo EI, Luostarinen ME, Salo JA. Fate of patients with adenocarcinoma of the esophagus and the esophagogastric junction: a population-based analysis. Am J Gastroenterol 2004;99(3):419-24
- Fujita H, Kakegawa T, Yamana H, et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg 1995;222(5):654-62
- Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg 1998;175(1):47-51
- Bonjer HJ, Hop WC, Nelson H, et al. Laparoscopic assisted versus open colectomy for colon cancer: a meta-analysis. Arch Surg 2007;142:298-303
- Luketich JD, Alvelo-Rivera M, Buenaventura PO et al. Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg 2003;238:486-94
- Palanivelu C, Prakash A, Senthilkumar R, et al. Minimally invasive esophagectomy: thoracoscopic mobilization of the esophagus and mediastinal lymphadenectomy in prone position – experience of 130 patients. J Am Coll Surg 2006;203(1):7-16
- Berrisford RG, Wajed SA, Sanders D, et al. Short-term outcomes following total minimally invasive oesophagectomy. Br J Surg 2008;95(5):602-10
- Smithers BM, Gotley DC, Martin I, et al. Comparison of the outcomes between open and minimally invasive esophagectomy. Ann Surg 2007;245(2):232-40
- Hölscher AH, Bollschweiler E, Schneider PM, et al. Early adenocarcinoma in Barrett's oesophagus. Br J Surg 1997;84(10):1470-3
- Nigro JJ, Hagen JA, DeMeester TR, et al. Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. Ann Surg 1999;230(3):433-8
- Stein HJ, Feith M, Bruecher BL, et al. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005;242(4):566-73
- Rice TW, Falk GW, Achkar E, et al. Surgical management of high-grade dysplasia in Barrett's esophagus. Am J Gastroenterol 1993;88(11):1832-6
- Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996;224(1):66-71
- Hölscher AH, Bollschweiler E, Schneider PM, et al. Early adenocarcinoma in Barrett's oesophagus. Br J Surg 1997;84(10):1470-3
- Nigro JJ, Hagen JA, DeMeester TR, et al. Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. Ann Surg 1999;230(3):433-8
- Stein HJ, Feith M, Bruecher BL, et al. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005;242(4):566-73
- Headrick JR, Nichols FC 3rd, Miller DL, et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg 2002;73(6):1697-702
- Altorki NK, Lee PC, Liss Y, et al. Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: implications for endoscopic treatment. Ann Surg 2008;247(3):434-9
- Stein HJ, Feith M, von Rahden BH, et al. Approach to early Barrett's cancer. World J Surg 2003;27(9):1040-6
- Banki F, Mason RJ, DeMeester SR, et al. Vagal-sparing esophagectomy: a more physiologic alternative. Ann Surg 2002;236(3):324-35
- Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000;118(4):670-7
- Pech O, May A, Gossner L, et al. Curative endoscopic therapy in patients with early esophageal squamous-cell carcinoma or high-grade intraepithelial neoplasia. Endoscopy 2007;39(1):30-5
- Katada C, Muto M, Manabe T, et al. Local recurrence of squamous-cell carcinoma of the esophagus after EMR. Gastrointest Endosc 2005;61(2):219-25
- Hage M, Siersema PD, van Dekken H, et al. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut 2004;53(6):785-90
- Kelty CJ, Ackroyd R, Brown NJ, et al. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther 2004;20(11-12):1289-1296
- Pech O, Behrens A, May AD, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008;6 [Epub ahead of print]
- Mariette C, Balon JM, Piessen G, et al. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003;97(7):1616-23
- Wayman J, Bennett MK, Raimes SA, et al. The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction. Br J Cancer 2002;86(8):1223-9
- Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997;114(2):205-9
- Pouliquen X, Levard H, Hay JM, et al. 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicentre randomized trial. French Associations for Surgical Research. Ann Surg 1996;223(2):127-33
- Ando N, Iizuka T, Ide H, et al. Japan Clinical Oncology Group. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology GroupStudy-JCOG9204. J Clin Oncol 2003;21(24):4592-6
- Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001;91(11):2165-74
- Cunningham D, Allum WH, Stenning SP, et al. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355(1):11-20
- Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339(27):1979-84
- Law S, Fok M, Chow S, et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997;114(2):210-7
- Maipang T, Vasinanukorn P, Petpichetchian C, et al. Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J Surg Oncol 1994;56(3):191-7
- Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359(9319):1727-33
- Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992;16(6):1104-10
- Roth JA, Pass HI, Flanagan MM, et al. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988;96(2):242-8
- Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg 1992;127(12):1446-50
- Malthaner RA, Collin S, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 2006;3:CD001556
- Cunningham D. Treatment of gastric cancer. N Engl J Med 2006;355(13):1387; author reply 1387-8
- Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19(12):3058-65
- Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24(29):4692-8
- Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON Phase II trial. Lancet Oncol 2007;8(9):797-805
- Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994;41(4):391-3
- Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337(3):161-7
- Burmeister BH, Smithers BM, Gebski V, et al. Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled Phase III trial. Lancet Oncol 2005;6(9):659-68
- Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73(7):1779-84
- Lee JL, Park SI, Kim SB, et al. A single institutional Phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for respectable esophageal squamous cell carcinoma. Ann Oncol 2004;15(6):947-54
- Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The Second Scandinavian Trial in Esophageal Cancer. World J Surg 1992;16(6):1104-10
- Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26(7):1086-92
- Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19(2):305-13
- Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335(7):462-7
- Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001;88(3):338-56
- Reynolds JV, Muldoon C, Hollywood D, et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 2007;245(5):707-16
- Gebski V, Burmeister B, Smithers BM, et al. Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8(3):226-34
- van de Schoot L, Romme EA, van der Sangen MJ, et al. A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer. Ann Surg Oncol 2008;15(1):88-95
- Suntharalingam M, Moughan J, Coia LR, et al. 1996–1999 Patterns of Care Study. The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996–1999 Patterns of Care Study. Int J Radiat Oncol Biol Phys 2003;56(4):981-7
- Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40
- Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326(24):1593-8
- Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281(17):1623-7
- Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23(10):2310-7
- Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25(10):1160-8
- Peters CJ, Fitzgerald RC. Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma. Aliment Pharmacol Ther 2007;25(11):1253-69
- Jankowski J, Coghill G, Hopwood D, et al. Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut 1992;33(8):1033-8
- Itakura Y, Sasano H, Shiga C, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994;74(3):795-804
- Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45
- Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007;298(1):70-82
- Safran H, Suntharalingam M, Dipetrillo T, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 2008;70(2):391-5
- Safran H, Dipetrillo T, Akerman P, et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;67(2):405-9
- Ferry DR, Anderson M, Beddard K, et al. A Phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007;13(19):5869-75
- Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24(30):4922-7
- Kleespies A, Guba M, Jauch KW, et al. Vascular endothelial growth factor in esophageal cancer. Surg Oncol 2004;87(2):95-104
- Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57(20):4593-9
- Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter Phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24(33):5201-6
- Reynolds JV, Ravi N, Hollywood D, et al. Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. J Thorac Cardiovasc Surg 2006;132:549-55
- Gillham CM, Lucey JA, Keogan M, et al. (18) FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphologic tumour response. Br J Cancer 2006;95:1174-9
- Gillham CM, Aherne N, Rowley S, et al. Quality of life and survival in patients treated with radical chemoradiation for oesophageal cancer. Clin Oncol (R Coll Radiol) 2008;20:227-33